Pfizer buys OPKO growth hormone drug
December 16, 2014Research and Development, Sales and Marketing Pfizer, ghd, growth, hGH-CTP, hormone, merger, opko
Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …
AstraZeneca closing US manufacturing unit
December 16, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, Pulmicort, malloy, short haircuts, westboro
AstraZeneca is closing its Otis Street manufacturing plant next year that has been in operation for 33 years, and the …
Riemser Pharma recruits former GSK head
December 16, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, riemser pharma, thomas werner
Riemser Pharma in Germany has appointed Dr Thomas Werner to its advisory board. The former head of GlaxoSmithKline and Bristol-Myers …
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
Abbott buys Russian firm Veropharm
December 15, 2014Manufacturing and Production, Sales and Marketing Abbott, Fresenius, cfr pharma, petrovax, sistema, veropharm, zenitco
Abbott has completed its purchase of Russia-based Veropharm in a $305 million deal as it looks to firmly establish itself …
Mixed bag for Novartis and Astellas in breast cancer
December 15, 2014Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus
Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …
Gilead sued over Sovaldi price
December 15, 2014Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
Celgene UK: market access is a complex business
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce
Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …
Vermillion takes on two senior heads
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing david schreiber, vermillion, veronica jordan
US drug development firm Vermillion has appointed Veronica Jordan and David Schreiber to the company’s board of directors. Dr Veronica …
Pharma to lose $69 billion in five years as patents expire
December 12, 2014Sales and Marketing AstraZeneca, GlobalData, Japanese firm Otsuka, Otsuka, lilly, pharma
Pharma companies are set to lose around $65 billion by 2019 due to drug patent expiries according to research firm …
Patient access schemes ‘lack transparency’
December 12, 2014Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme
Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …
Gavi pledges $300 million for Ebola vaccines
December 12, 2014Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink
The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …
PPRS scheme payment percentage to rise by 6.62% in 2015
December 12, 2014Sales and Marketing ABPI, PPRS, VBP, Whitehead, government, medicines bill
The amount of payment due from pharma via the PPRS scheme for next year has been confirmed by the Department …
NICE changes insulin advice in diabetes guidelines
December 12, 2014Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …
Unilife appoints comms VP from Intel
December 12, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing kevin sellers, unilife
US developer of injectable drugs Unilife has looked to Intel to appoint a marketing and communications veteran in Kevin Sellers. …
Antibiotic resistance could kill 10 million a year
December 11, 2014Research and Development, Sales and Marketing Antibiotics, Cancer, KPMG, Merck, david cameron, rand
Antibiotic-resistant bacteria will kill an extra 10 million people a year by 2050 if the problem is not tackled soon, …
Sanofi looking to diversify, may buy into animal health
December 11, 2014Manufacturing and Production, Research and Development, Sales and Marketing EFPIA, Jimenez, Sanofi, Serge Weinberg, Viehbacher, animal health
Sanofi is looking to diversify and is even considering buying into the consumer and animal health markets according to its …
Takeda eyes new drug licences following positive blood cancer studies
December 11, 2014Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology
Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …
Boehringer trials Pradaxa anti-bleeding antidote
December 11, 2014Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab
Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …
Mylan shells out $32.5m to cover tax inversion fines
December 11, 2014Sales and Marketing AbbVie, Abbott, Mylan, SEC, bresch, coury
Mylan will pay five of its top executives an early $32.5 million to cover penalties from the company’s plans to …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
